A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging
Phase of Trial: Phase I/II
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Ischemia-tolerant mesenchymal stem cells (Primary)
- Indications Photodamage; Skin aging
- Focus Adverse reactions
- Sponsors Stemedica Cell Technologies
- 16 Apr 2018 Planned End Date changed from 1 Nov 2017 to 1 May 2019.
- 16 Apr 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 13 Oct 2016 Status changed from recruiting to suspended.